Background
B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), represent aggressive malignancies with significant unmet therapeutic needs, particularly in relapsed or refractory cases. Protein arginine methyltransferase 5 (PRMT5) has been implicated in oncogenic signaling, but its role in lipid metabolism and ferroptosis—a form of regulated cell death driven by iron-dependent lipid peroxidation—remains poorly understood. This study elucidates a novel mechanism by which PRMT5 inhibition sensitizes lymphoma cells to ferroptosis, offering a potential breakthrough in treatment strategies.
Study Design
The study employed in vitro and in vivo models, including patient-derived xenografts (PDX), to investigate the role of PRMT5 in ferroptosis resistance. Key interventions included the PRMT5 inhibitor GSK3326595 and the ferroptosis inducer dimethyl fumarate (DMF). Mechanistic insights were derived from analyses of the AKT-MYC-ATF5 signaling axis and its downstream targets, SLC7A11 and ATF4.
Key Findings
PRMT5 was found to suppress ferroptosis in DLBCL and MCL cells by upregulating SLC7A11, a cystine importer critical for glutathione (GSH) biosynthesis. This effect was mediated via the AKT-MYC-ATF5 axis, with ATF5 promoting both SLC7A11 and ATF4 expression. Notably, PRMT5 inhibition synergized with DMF to enhance ferroptotic cell death and anti-tumor activity in PDX models, highlighting a promising combinatorial approach.
Expert Commentary
The discovery of the PRMT5-ATF5-SLC7A11 axis provides a mechanistic basis for targeting ferroptosis resistance in B-cell lymphomas. While the findings are compelling, further validation in clinical trials is needed to assess efficacy and safety in humans. The study’s use of PDX models enhances translational relevance, but limitations include the need for broader testing across lymphoma subtypes.
Conclusion
This study identifies PRMT5 as a critical regulator of ferroptosis resistance in B-cell lymphomas, unveiling a novel therapeutic axis. The combination of PRMT5 inhibitors and ferroptosis inducers like DMF warrants clinical investigation, particularly for relapsed or refractory disease. These findings bridge a critical gap in understanding lipid metabolism’s role in lymphoma biology and therapy.
Funding and ClinicalTrials.gov
The study was supported by institutional and grant funding, with details available in the original publication. ClinicalTrials.gov registration numbers were not provided.
References
Liu Y, et al. PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis. Leukemia. 2026.
